| INDUSTRY NEWS | Food and Drug Administration (FDA) Approves Dendreon’s Atlanta Cancer Immunotherapy Manufacturing Facility Dendreon Corporation announced that the U.S. FDA approved its Atlanta cancer immunotherapy manufacturing facility, the third location at which the company will produce PROVENGE® (sipuleucel-T) to help meet the needs of patients across the U.S. with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. [Dendreon Corporation] Press Release University of Southern Carolina (USC) Institute of Urology Adds New Technology Detection of prostate cancer just became more accurate at the USC Institute of Urology, thanks to the addition of new technology, some of the first available in the United States. [University of Southern Carolina] Press Release Britain to Launch Personalized Medicine Project – Pilot Programme Will Combine Genetic Tests with Centralized Data Led by the charity Cancer Research UK, the Stratified Medicine Program will enroll 9,000 people with breast, colorectal, lung, prostate, ovarian and skin cancer in the first, two-year phase of the project. [NatureNews] Press Release Adamis Pharmaceuticals Begins Prostate Cancer Trial Adamis Pharmaceuticals Corporation announced that it enrolled the first patient in its Phase 1/2a clinical prostate study. [Business Wire] Press Release |
|
|
|